Systems-immunology repurposing for inflammatory atherosclerosis
A systems-immunology workflow integrates mass cytometry, RNA sequencing, large-scale perturbational gene-expression data, and human ASCVD plasma to identify repurposing candidates. Saracatinib reversed inflammatory signatures ex vivo, reduced atherosclerosis in mice, reprogrammed reparative macrophages, and reduced plaque inflammation in a rabbit model.
About University of Cambridge
Cambridge is a collegiate, comprehensive research university that combines broad academic depth with world-class facilities and strong translational activity. Industry engages through co-located labs, a major biomedical campus integrated with an NHS hospital system, and research and technology parks across the Cambridge cluster. Its location in a mature startup and scale-up ecosystem provides ready access to venture funding, prototyping resources, and collaboration with global R&D sites. Research is backed by competitive UKRI council funding and other national sources, with additional support from major charities and European programs. A dedicated technology transfer office supports IP, licensing, and seed investment to accelerate commercialization.
delivered to your inbox.